Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (3227)	1/8/2003 1:23:55 PM
From: Sergio H	Read Replies (1) \| Respond to of 37387

Crossy, CLGY's Tostrex will get a decision from the FDA in early April. This could be a big winner for CLGY followed by the female version of the drug, Tostrelle right after. CLGY's homepage has good info. Here's their pipeline and the status of each drug: cellegy.com In answer to your question about market size, take a glance at the private study from BioInnovators: cellegy.com I have been trying to alert people to the special situation that is currently in play. Check out the insider purchases by Mr. Gregory, the former CEO of King Pharmaceuticals. Since Oct. he bought over a quarter of CLGY's shares at market prices. The buying is still going on this week. CLGY took a dive last year when the NDA for their lead drug was withdrawn. Tostrex and Tostrelle have larger market potential and more than make up for the prior set back. This is an exciting play right now with several developments in the works. Sergio